Reading IMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IMA free→Reading IMA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track IMA free→QuarterlyIQ Insights · IMA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 7, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities o…
The Company expects to use the net proceeds from the Closing of the Private Placement, together with the Company’s existing cash and cash equivalents, to support late-phase development readiness in atopic dermatitis, expand development of IMG-007 into additional indications, including alopecia areata. The securities described above under
Entry into a Material Definitive Agreement. Securities Purchase Agreement On April 12, 2026, ImageneBio, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue pre-funded warrants to purchase shares of the Company’s voting common stock, par value $0.001 (“Common Stock” and the shares subject to the pre-fund…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 12, 2026, ImageneBio, Inc. (the “Company”) and Erin Butler, the Company’s Senior Vice President, Finance & Administration and Principal Accounting Officer, agreed to a mutual separation effective March 20, 2026 (the “Butler Separation Date”). Effective as of the Butler Separation Date, Ms. Butler will no longer serve as the Company’s Princ…
Results of Operations and Financial Condition On March 10, 2026, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter and fiscal year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subjec…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 12, 2026, Steven Hui Wang resigned as a member of the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”), effective immediately. Mr. Wang’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy. SIGNATURE Pursuant to the re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2025, Yufang Lu, M.D., Ph.D., our Chief Medical Officer, provided notice of her resignation, effective December 31, 2025. Dr. Lu’s resignation was not due to any disagreement on any matter relating to our operations, policies or practices. We are conducting a search for Dr. Lu’s replacement. Dr. Lu is expected to provide transition…
Results of Operations and Financial Condition On November 12, 2025, ImageneBio, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the lia…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On November 1, 2025, the Board of Directors (the “Board”) of ImageneBio, Inc. (the “Company”) increased the authorized size of the Board from six directors to seven directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Joseph P. Slattery to the Board, effective November 1, 2025, and as t…
Termination of a Material Definitive Agreement. To the extent required by
Entry into a Material Definitive Agreement. On October 23, 2025, we provided written notice (the “Notice”) of our election to (i) not have that certain transition services agreement, dated July 25, 2025 (the “Agreement”) with Miragene Inc., an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands (“Miragene”), automatically renew under the current service terms and (ii) extend the term for six months following the end of the initial term for a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (c) On October 21, 2025, the board of directors of ImageneBio, Inc. (the “Company”) appointed Kristin Yarema, Ph.D., the Company’s Chief Executive Officer, as the Company’s interim principal financial officer, effective immediately. Dr. Yarema’s biographical information is set forth under the section titled “Management” in the Company’s registratio…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 10, 2025, Jotin Marango, M.D., Ph.D., our Chief Financial Officer and principal financial officer, provided notice of his resignation, effective October 20, 2025. Dr. Marango’s resignation was not due to any disagreement with the Company. We plan to conduct a search for Dr. Marango’s replacement. SIGNATURE Pursuant to the requirements of…
of the Original Report to include Management’s Discussion and Analysis of Financial Condition and Results of Operations of Inmagene (as defined in the Original Report) for the three and six months ended June 30, 2025 and 2024; and (ii) include the unaudited interim condensed financial statements of Inmagene as of and for the three and six months ended June 30, 2025 and 2024 under Item 9.01(a) of the Original Report. This Amendment No. 1 does not amend any other item of the Original Report or…
Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On August 2, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of ImageneBio, Inc. (formerly Ikena Oncology, Inc.) (the “Company”) dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective on August 2, 2025 (the “Effective Time”). EY’s audit reports on the Company’s consolidated…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. To the extent required by
Other Events. Ikena Oncology, Inc. (“Ikena”) today announced that it will effect a 1-for-12 reverse stock split of Ikena’s common stock, par value $0.001 per share (“Ikena common stock”) that is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market (“Nasdaq”) on July 28, 2025, under the new name “ImageneBio, Inc.”, ticker symbol “IMA”, CUSIP number 45175G207 and ISIN number US45175G2075. The reverse stock split effects all issued and outstanding shares of…
Other Events As previously announced, on December 23, 2024, Ikena Oncology, Inc., a Delaware corporation (“Ikena”), Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub I”), Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub II”),…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 15, 2025, Ikena Oncology, Inc. (the “Company”) entered into an amendment to its employment agreement with Jotin Marango, M.D., Ph.D., effective as of July 15, 2025 (the “Employment Agreement Amendment”). The Employment Agreement Amendment provides for certain additional benefits to Dr. Marango in the event that his employment is terminated…
Other Events. On July 15, 2025, Ikena issued a press release announcing the results of the voting proposals from the Annual Meeting, as well as certain information with respect to the reverse stock split of Ikena common stock. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference. Based on the results of the Annual Meeting, the Merger and the Ikena concurrent financing are expected to be consummated around the end of July, subject to the satisfact…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2025 Equity Incentive Plan At the annual meeting of the stockholders of Ikena Oncology, Inc. (“ Ikena ”) held on July 15, 2025 (the “ Annual Meeting ”), Ikena’s stockholders considered and approved the 2025 Equity Incentive Plan (the “ 2025 Plan ”), which will become effective on the date immediately following the date of the consummation of the Me…
Other Events. As previously announced, on December 23, 2024, Ikena Oncology, Inc., a Delaware corporation (“Ikena”), Insight Merger Sub I, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub I”), Insight Merger Sub II, an exempted company with limited liability incorporated and existing under the laws of the Cayman Islands and direct wholly owned subsidiary of Ikena (“Merger Sub II”)…
Other events. On July 1, 2025, Inmagene announced the successful dosing of the first patient in its ADAPTIVE Trial of IMG-007 in patients with moderate-to-severe AD. Forward-Looking Statements This Current Report on Form 8-K and the exhibits filed or furnished herewith contain “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Inmagene’s and Ikena’s actual results may differ from their expectations, estimate…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.